
The FDA issued a complete response letter to the biologics license application for ivonescimab for use in combination with chemotherapy in EGFR-mutated NSCLC.
A 62-Year-Old Male With Stage III Non-Small Cell Lung Cancer
Case: A 62-Year-Old Male With Stage III NSCLC
Initial presentation
Clinical workup
Treatment





